Patents by Inventor Venkat Reddy Mali

Venkat Reddy Mali has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12054484
    Abstract: Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (Ia1?): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: August 6, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Junfa Fan, Jaroslaw Kalisiak, Rebecca M. Lui, Venkat Reddy Mali, Jeffrey P. McMahon, Jay P. Powers, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • Patent number: 12011439
    Abstract: The present disclosure is drawn to the combination therapy of a C-C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.
    Type: Grant
    Filed: August 16, 2022
    Date of Patent: June 18, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Shijie Li, Venkat Reddy Mali, Rajinder Singh, Ju Yang, Penglie Zhang
  • Publication number: 20240109877
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4A, R4b, and R5, are as defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL.
    Type: Application
    Filed: March 21, 2023
    Publication date: April 4, 2024
    Inventors: Zhiguo Bian, Jason P. Burke, Zhaozhong J. Jia, Xingyu Jiang, Matthew H. Katcher, Venkat Reddy Mali, Violeta L. Marin, Elizabeth L. Noey, Akinori Okano, Alexey A. Rivkin, Spencer O. Scholz, Kevin R. Woller, Xianrui Zhao, Ashley M. Adams, Berenger Biannic, Shahab Mortezaei, Joshua N. Payette, Jeffery A. Zablocki
  • Patent number: 11884654
    Abstract: Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: January 30, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Trevor T. Charvat, Junfa Fan, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Venkat Reddy Mali, Jeffrey P. McMahon, Jay Powers, Sreenivas Punna, Ju Yang
  • Patent number: 11872217
    Abstract: Compounds represented by Formula (I) or (II): are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R2a?, R2b?, R2c?, R3?, R4?, R5?, R6a?, R6b?, Y, Y?, and the subscripts m and n are as defined herein.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: January 16, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Viengkham Malathong, Venkat Reddy Mali, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Ju Yang, Penglie Zhang
  • Patent number: 11807609
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: November 7, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Rebecca M. Lui, Venkat Reddy Mali, Rajinder Singh, Yibin Zeng, Penglie Zhang
  • Patent number: 11773091
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: October 3, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • Patent number: 11708326
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: July 25, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Christopher Lange, Viengkham Malathong, Venkat Reddy Mali, Jeffrey McMahon, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Yu Wang, Ju Yang, Penglie Zhang
  • Patent number: 11684606
    Abstract: The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: June 27, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: James J. Campbell, Karen Ebsworth, Antoni Krasinski, Venkat Reddy Mali, Jeffrey McMahon, Rajinder Singh, Ju Yang, Chao Yu, Penglie Zhang
  • Publication number: 20230151002
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: May 3, 2022
    Publication date: May 18, 2023
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Viengkham MALATHONG, Venkat Reddy MALI, Sreenivas PUNNA, Rajinder SINGH, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
  • Publication number: 20230115912
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: September 13, 2022
    Publication date: April 13, 2023
    Inventors: Pingchen FAN, Christopher W. LANGE, Viengkham MALATHONG, Venkat Reddy MALI, Sreenivas PUNNA, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
  • Publication number: 20230097128
    Abstract: The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.
    Type: Application
    Filed: August 16, 2022
    Publication date: March 30, 2023
    Inventors: Shijie LI, Venkat Reddy MALI, Rajinder SINGH, Ju YANG, Penglie ZHANG
  • Patent number: 11608336
    Abstract: The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: March 21, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Rebecca M. Lui, Rajinder Singh, Venkat Reddy Mali, Yibin Zeng, Penglie Zhang
  • Publication number: 20230044941
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: January 14, 2022
    Publication date: February 9, 2023
    Inventors: Pingchen FAN, Christopher LANGE, Venkat Reddy MALI, Darren J. McMURTRIE, Viengkham MALATHONG, Sreenivas PUNNA, Rajinder SINGH, Ju YANG, Yibin ZENG, Penglie ZHANG
  • Patent number: 11485737
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: November 1, 2022
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Yibin Zeng, Penglie Zhang
  • Patent number: 11485708
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R5, R6, R7, R8 and the subscript n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: November 1, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Viengkham Malathong, Pingchen Fan, Christopher Lange, Venkat Reddy Mali, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Ju Yang, Penglie Zhang
  • Patent number: 11478460
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: October 25, 2022
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • Patent number: 11479553
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: October 25, 2022
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Yibin Zeng, Penglie Zhang
  • Patent number: 11446289
    Abstract: The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: September 20, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Shijie Li, Venkat Reddy Mali, Rajinder Singh, Ju Yang, Penglie Zhang
  • Publication number: 20220280481
    Abstract: The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist.
    Type: Application
    Filed: November 16, 2021
    Publication date: September 8, 2022
    Inventors: James J. CAMPBELL, Karen EBSWORTH, Antoni KRASINSKI, Venkat Reddy MALI, Jeffrey McMAHON, Rajinder SINGH, Ju YANG, Chao YU, Penglie ZHANG